The primary objective of our centre is to translate recent huge advances in the basic understanding of the pathogenesis of coeliac disease to the clinic – to improve disease diagnostics, to implement novel treatments and to identify new therapeutic targets for this common disease.
The secondary objective is to become a clinical research site at the international forefront which will provide optimal patient care and which will be a unique training site for basic scientists and clinicians.
News
-
Machine intelligence to tackle the complexity of adaptive immune receptors
Nov. 18, 2021 3:58 PM
This November, Milena Pavlović and Lonneke Scheffer, PhD students in the group of prof. Geir Kjetil Sandve at the Department of Informatics (UiO) published their computational framework Immune ML in Nature Machine Intelligence. ImmuneML is a freely available tool that allows researchers to tackle complex computational questions related to studies of adaptive immune receptor repertoires. This tool will be an important resource for all studies that link B cell receptor and T cell receptor sequence data to antigen recognition and disease. For celiac disease, this represents one step closer towards the goal of detecting genes of gluten specific T cells directly in blood.
-
Transglutaminase 2 inhibitor shows great promise in clinical trial
Sep. 29, 2021 10:44 AM
Transglutaminase 2 (TG2) activity is essential to induce a pathogenic immune response towards gluten in coeliac disease. In a Phase 2 clinical trial, a daily dose of an irreversible TG2-inhibitor prevented gluten-induced mucosal destruction in coeliac patients that consumed gluten daily for 6 weeks. These findings represents a milestone in the search for treatment options for patients with coeliac disease.
Publications
- KIR<sup>+</sup>CD8<sup>+</sup> T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19 Mar. 8, 2022 10:00 AM
- Injection of prototypic celiac anti-transglutaminase 2 antibodies in mice does not cause enteropathy Apr. 6, 2022 11:00 AM
- Epstein-Barr virus as a driver of multiple sclerosis Apr. 1, 2022 11:00 AM
